Drug Search Results
More Filters [+]

Talarozole

Alternative Names: talarozole
Latest Update: 2024-04-28
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: CYP26 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Stiefel
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Talarozole

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Psoriasis|Other

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

BT0720-201-INT

P2

Completed

Psoriasis

2007-05-01

BT0700BEL001

P2

Completed

Other

2005-07-01

BT0700NED001

P2

Completed

Psoriasis

2005-03-01

Recent News Events